Valuation: Prenetics Global Limited

Market Cap 368M 323M 300M 276M 518M 35.52B 528M 3.58B 1.4B 17.35B 1.38B 1.35B 60.27B P/E 2026 *
-7.45x
P/E 2027 * -76x
Enterprise Value 368M 323M 300M 276M 518M 35.52B 528M 3.58B 1.4B 17.35B 1.38B 1.35B 60.27B EV / Sales 2026 *
1.7x
EV / Sales 2027 * 0.97x
Free-Float
85.05%
Yield 2026 *
-
Yield 2027 * -
1 day-11.16%
1 week-0.82%
Current month+1.57%
1 month-2.71%
3 months+8.13%
6 months+2.75%
Current year+23.30%
1 week 17.18
Extreme 17.18
22.75
1 month 15.91
Extreme 15.91
22.75
Current year 14
Extreme 14
23.63
1 year 7.18
Extreme 7.175
23.63
3 years 2.85
Extreme 2.85
23.63
5 years 2.85
Extreme 2.85
131.25
10 years 2.85
Extreme 2.85
131.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 52 2013-12-31
Chief Executive Officer 47 2013-12-31
Director of Finance/CFO 41 2017-12-31
Director TitleAgeSince
Chairman 47 2013-12-31
Director/Board Member 38 -
Director/Board Member 60 2024-06-12
Date Insider Type Main position Quantity % Market Cap.
7/10/26 Other

CFO of IM8 (US) LLC

56,851 0.3729%
7/4/26 Fiscal year

Director

4,000 0.0262%
6/15/26 Fiscal year

Director

31,746 0.2082%
Change 5-day change 1-year change 3-year change Capi.($)
-11.16%-0.82%+139.16%+59.84% 368M
+0.18%+12.86%-19.87%-11.85% 175B
+0.15%+1.91%-10.52%-7.81% 105B
+1.49%+2.86%+4.13%+58.40% 58.48B
-0.82%-1.93%+38.23%+58.17% 51.36B
-0.12%-1.23%-15.62%-42.24% 42.2B
+1.21%-4.59% - - 31.44B
-1.33%-3.09%-17.20%-46.03% 27.56B
-0.82%-0.98%+62.39%-5.79% 25.32B
+0.03%-0.39%-5.83%-9.24% 20.52B
Average -1.12%+1.71%+19.43%+5.94% 53.73B
Weighted average by Cap. +0.12%+3.98%-3.95%+0.28%

Financials

2026 *2027 *
Net sales 216M 190M 176M 162M 304M 20.86B 310M 2.1B 822M 10.19B 811M 793M 35.39B 378M 332M 308M 284M 532M 36.46B 542M 3.68B 1.44B 17.8B 1.42B 1.39B 61.85B
Net income -69.45M -61.04M -56.72M -52.16M -97.8M -6.71B -99.67M -676M -264M -3.27B -261M -255M -11.38B -5.67M -4.98M -4.63M -4.26M -7.99M -548M -8.14M -55.23M -21.57M -267M -21.28M -20.83M -929M
Net Debt - -
Logo Prenetics Global Limited
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
Employees
98
Date Price Change Volume
26-07-23 US$19.42 -11.16% 258,929
26-07-22 US$21.86 -0.88% 310,642
26-07-21 US$22.06 +5.88% 437,474
26-07-20 US$20.83 +13.89% 291,812
26-07-17 US$18.29 -3.28% 134,131
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
19.42USD
Average target price
34.20USD
Spread / Average Target
+76.11%

Quarterly revenue - Rate of surprise